Selling an opioid treatment program requires a workable answer to a basic question: who will be authorized, staffed and ready to care for patients when ownership changes? An attractive offer does not settle that question. SAMHSA certification, accreditation, DEA requirements, state oversight and payer enrollment create separate workstreams. This guide focuses on the ownership-transfer decisions an OTP seller should resolve before committing to a closing date, including the financial consequences of delays and the practical handoff that keeps treatment running.
An OTP is a specific regulated treatment model. A practice offering office-based buprenorphine treatment, a residential addiction treatment center and a federally certified OTP can have different requirements. Start by identifying exactly which services and locations the buyer is acquiring. Avoid applying an OTP checklist to every medication-based treatment practice simply because their services overlap.
SAMHSA’s Part 8 guidance explains the federal framework for OTP certification, accreditation and treatment. The 2024 changes did not authorize methadone prescribing outside OTPs for opioid use disorder. That distinction matters when a buyer proposes consolidating locations, changing the care model or moving services into an existing practice. Operational integration needs its own regulatory review.
Treat the proposed closing date as a date that must be supported by evidence. The requirements depend on the entities, locations, transaction structure and jurisdictions involved. One agency’s acknowledgment cannot establish that every other approval, notice or billing requirement has been satisfied. For the broader process, see the sister-site guide to selling an addiction treatment center.
Ask counsel to draw the legal organization before and after the transaction. Identify the entity holding each certification, registration, license, accreditation and payer agreement. Record the owners, controlling parties, tax identifiers, primary dispensing locations and medication units. A buyer acquiring equity in an existing entity creates different questions from a buyer acquiring assets into a new entity.
Then list proposed operational changes separately: a new program sponsor, replacement medical director, new legal name, relocated dispensing unit or additional medication unit. A sale can trigger several changes together, but regulators may treat them separately. An equity structure should not be assumed to eliminate change-of-control notices or consent requirements.
A useful requirements schedule gives every item an accountable person, required filing, submission status, effective date and evidence needed before closing. Include what happens if the item is delayed. Keep entity names consistent across the agreement and applications; an unexplained mismatch between the buyer named in the purchase agreement and the proposed enrolled provider deserves resolution before signatures. The sister-site addiction treatment provider due diligence guide covers the wider review; this schedule should focus on ownership-transfer dependencies.
Build the schedule around the actual agencies and organizations involved. Four categories deserve distinct ownership:
SAMHSA’s program-change instructions distinguish ownership changes reported to its Division of Pharmacologic Therapies or the relevant compliance officer from sponsor and medical-director changes submitted through SMA-162. The latter must be reported within three weeks. Certain location and medication-unit changes require approval. Ask for instructions tailored to the transaction rather than assuming one filing covers everything.
An ownership transition should have a documented operating plan that the clinical and dispensing leaders can execute. Work through these practical responsibilities:
DEA’s Form 222 guidance confirms that transfers of Schedule I or II inventory between registrants carry specific order-form requirements. The purchase agreement should not be treated as permission to move medication. The clinical plan should also preserve individualized treatment decisions; ownership economics should not dictate dosing or take-home eligibility.
Clinical operating authority and payer billing authority need separate verification. CMS’s OTP enrollment guidance requires full SAMHSA certification and approved accreditation for Medicare enrollment. Although the OTP benefit is Part B, institutional providers and professional suppliers have different enrollment routes, including CMS-855A and CMS-855B respectively. Confirm the program’s actual classification with its Medicare Administrative Contractor.
For every material payer, establish the contracting entity, enrollment status, change requirements, provider identifiers and expected effective date. Review Medicaid requirements and managed-care contracts separately. Ask how authorizations, claims submission, remittances and denials will be handled across the service-date cutover. A statement that the buyer already accepts a payer elsewhere is insufficient evidence that this location can submit payable claims under the proposed arrangement.
Model the cash requirement if valid claims cannot be submitted or paid immediately. Decide who funds payroll and medication purchases during that period, who owns pre-closing receivables and who handles rejected or misdirected payments. Any transition billing arrangement needs specific reimbursement and legal review. Continuing to bill under the seller’s identifiers simply because they still work can create a serious problem.
Once the requirements are understood, reflect their economic consequences in the transaction documents. The seller should be able to explain these four items without relying on an informal assurance:
The letter of intent is the point to expose major closing assumptions before exclusivity narrows your options. For example, if the buyer’s offer assumes every location remains open and every payer arrangement continues, document that premise. Then determine what happens if a consent is refused or a site needs a different operating arrangement.
Patient records need their own disclosure and custody plan. HHS states that applicable changes to 42 CFR Part 2 required compliance by February 16, 2026. Counsel should assess which records are protected, the lawful disclosure pathway and any consent restrictions. A buyer’s NDA alone does not establish permission to receive identifiable treatment records.
Begin commercial evaluation with appropriately prepared aggregate information where it can answer the question. When patient-level review is necessary and authorized, limit access to the people and information needed, track disclosure and specify retention or return requirements. At closing, settle custody, access for ongoing care, response to patient requests and support for permitted audits. Test the handoff without using the transaction as a reason to broaden access indiscriminately.
An addiction treatment M&A advisor can coordinate buyer discussions, terms and the overall process. Healthcare regulatory counsel should interpret the applicable ownership-change requirements. Reimbursement specialists should verify enrollment and billing assumptions, while tax advisors assess structure. Ask prospective buyers who will manage their regulatory submissions and operating transition, what work they have already completed, and which dependencies remain unresolved. The seller needs an accountable counterpart for each workstream.
Gather the entity chart, current certifications and licenses, accreditation documents, registration details and payer list. Identify proposed changes and ask the transaction team to produce a requirements schedule. Resolve uncertainty before promising a closing date or agreeing to a payment structure that shifts unpriced transition risk back to you.
Tony Siebel is the Founder and Managing Director of Olympic M&A. His background includes corporate development and physician-practice acquisitions at MDVIP, as well as serving as Vice President and Associate Partner at Stoneridge Partners, including work in its Behavioral Health Division.
Olympic M&A advises founders and healthcare business owners on transactions with private equity groups and strategic acquirers. Learn more about the firm’s behavioral health advisory services and discuss the scope of support appropriate for your business.
Contact Olympic M&A | info@olympicma.com | 502.360.8320